Biotech Startups

Grand River Aseptic Manufacturing (GRAM) is a contract development and manufacturing organization (CDMO) specializing in sterile fill-finish and aseptic manufacturing of injectable pharmaceutical and biologic products. It serves pharmaceutical and biotech clients across the drug product lifecycle, from development through commercial supply.

2 investors

Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options. The company is based in Basel, Switzerland, with a pipeline including Minokitug for autoimmune inflammation and GRT-002 for allergy and itch conditions.

2 investors

Grannus Therapeutics develops Hsp90 inhibitors that selectively target the beta isoform of the Hsp90 protein for cancer treatment. Its lead candidate, GRE317, is designed for single-agent anti-tumor activity and combination with therapies such as PARP inhibitors and immunotherapies, with programs advancing toward IND-enabling milestones and clinical studies.

2 investors

Graviton develops immunomodulatory therapies for patients with fibrotic, autoimmune, and central nervous system diseases. The company targets multiple molecular pathways to reduce disease burden and restore biological balance.

2 investors

GutGutGoose sequences a customer's gut microbiome, then compounds personalized probiotic formulas of 8-20 strains matched to their individual gut, diet, health history, and metabolic pathways, with a retest at 90 days to measure colonization. The consumer subscription product is sold in the US and Australia.

2 investors

Haima Therapeutics is a pre-clinical stage biopharma company developing cell-inspired therapies for bleeding and blood-related diseases, with an initial focus on platelet-inspired treatments for active bleeding and bleeding risks from trauma, surgery, thrombocytopenia, and rare bleeding disorders. Its lead technology, SynthoPlate, is a fully-synthetic hemostatic agent that acts at the injury site to amplify the body's natural clotting mechanisms.

2 investors

Halmos Labs provides automated biotech research and development, running experiments and simulations that address questions from wetlab experiment design through cancer vaccine manufacturing. It serves biotech and pharmaceutical research teams.

2 investors

HanchorBio is a biotech company developing innovative immunotherapy drugs for cancer treatment through translational medicine, moving from early research to clinical applications.

2 investors

Hanimune Therapeutics develops therapeutics for food allergy prevention and tolerance support for pediatric and adult patients, drawing on immunological science and food protein research.

2 investors

Happy Bond makes shelf-stable, fresh dog food products made with human-grade ingredients and gently cooked using patent-pending technology. The company serves pet owners seeking nutritionally complete meals for dogs without artificial preservatives or synthetic additives.

2 investors

Harbor MedTech develops collagen-based medical devices and bioimplants for surgical wound healing and tissue regeneration. The company's BriDGE technology platform produces products for orthopedic, general surgical, and chronic wound care applications.

2 investors

Harness Therapeutics develops disease-modifying precision therapies for hard-to-treat neurodegenerative diseases through controlled modulation of CNS targets. Its pipeline targets conditions including Huntington's disease, Parkinson's disease, Alzheimer's disease, and ALS, using expertise in RNA biology and targeted protein modulation.

2 investors

HBVtech develops a gene therapy platform intended to treat chronic infections with a single injection. Its lead program targets chronic hepatitis B (cHBV) infections, aiming for a lasting cure through one administration.

2 investors

Headlamp Health builds Lumos AI, a platform that consolidates fragmented patient data into a longitudinal view to support care, research, and therapeutic development in precision neuroscience. It serves clinicians, researchers, and drug developers working to match patients with the right treatments.

2 investors

HealthBiome is a South Korean biotech venture developing microbiome-based therapeutics targeting intractable diseases such as cancer, dementia, and metabolic disorders. The company focuses on strictly anaerobic, hard-to-culture gut microbiome strains, with capabilities in large-scale anaerobic cultivation, multi-omics analysis, and preclinical animal testing.

2 investors

HeartGenetics develops personalized genetic tests and reports for cardiovascular health, pharmacogenetics, and wellness using a DNA microchip platform and computational algorithms. The company serves healthcare providers and patients seeking genetic insights for preventive and personalized medicine.

2 investors

Heartbeat.bio develops cardiac chamber models (Cardioids) and an assay suite that characterize heart disease phenotypes at structural, functional, and molecular levels. The company applies these models to accelerate and de-risk cardiac drug discovery.

2 investors

Helaxy develops next-generation sequencing (NGS) testing solutions for hospitals and clinical laboratories, making molecular diagnostics more accessible and easier to implement in routine care.

2 investors

Helex is a biotech company whose team specializes in molecular biology, drug delivery, biomedical engineering, and nanotechnology research.

2 investors

Helical offers an AI platform for drug discovery that tunes bio foundation models to a customer's own biology and lab data, orchestrating them into ranked, mechanistically grounded candidate shortlists for target identification and biomarker discovery. It is built for biopharma R&D teams and provides model-agnostic harnesses, benchmarking, and enterprise deployment with data controls.

2 investors

Hememics develops FAST (Functionalized Analyte Screening Technology), an immunoassay-based screening platform that lets researchers use their own antibodies and antigens to screen antibody mini-panels in under an hour. Positioned as a faster, lower-cost alternative to ELISA, it delivers digital end-point results using a 96-well plate and a compatible reader.

2 investors

Hepta develops LiquidTransformer, an AI platform for analyzing cell-free DNA fragments in blood to detect chronic disease molecular signals. The platform uses transformer-based models with attention mechanisms to identify disease biomarkers from liquid biopsy samples.

2 investors

Herantis Pharma is a public pharmaceutical company listed on Nasdaq First North Growth Market Finland, focused on developing therapeutic treatments.

2 investors

Hermes Biosciences develops a benchtop extracellular vesicle isolation system that purifies exosomes from bodily fluids and cell culture media for research and clinical applications in oncology, degenerative disease, and regenerative medicine.

2 investors